|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
|
|---|---|---|
| Operating expenses: | ||
| Research and development | ||
| General and administrative | ||
| Total operating expenses | ||
| Loss from operations | ||
| Interest income | ||
| Interest expense | ||
| Net change in fair value of redeemable convertible preferred stock tranche obligations | ||
| Change in fair value of derivative liabilities | ||
| Loss on extinguishment of convertible notes | ||
| Other expense, net | ||
| Net loss | ||
| Other comprehensive loss: | ||
| Unrealized gain on marketable securities | ||
| Comprehensive loss | ||
| Net loss per share attributable to common stockholders, basic | ||
| Net loss per share attributable to common stockholders, diluted | ||
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic | ||
| Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted |
Loading...
